Overview

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.
Phase:
Phase 1
Details
Lead Sponsor:
Merrimack Pharmaceuticals
Collaborator:
Sanofi
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel